Safety of GANFORT® Ophthalmic Solution in Chinese Patients With Open-angle Glaucoma or Ocular Hypertension
Study Identifier
192024-094
CT.gov Identifier
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact
Study Complete
Study Details
Medical Condition
Study Drug
Phase
Phase 4
Sex
Female & Male
Age
18+ years
Protocol Summary
A study to evaluate the long-term safety of GANFORT® (bimatoprost 0.03% plus timolol 0.5%) in Chinese patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta-blocker or prostaglandin analogues.
Study Locations
Location
Status
Location
Beijing Hospital
Beijing, Beijing Municipality, China, 100005
Status
Not applicable
Location
Xuanwu Hospital Capital Medical University
Beijing, Beijing Municipality, China, 100053
Status
Not applicable
Location
Peking University Third Hospital
Beijing, Beijing Municipality, China, 100191
Status
Not applicable
Location
Beijing Tongren hospital Capital Medical University
Beijing, Beijing Municipality, China, 100730
Status
Not applicable
Location
Zhongshan Ophthalmic Center, Sun Yat-Sen University
Guangzhou, Guangdong, China, 510060
Status
Not applicable
Location
Tongji Hospital of Tongji Medical College, Huazhong University of Science & Technology
Wuhan, Hubei, China, 430030
Status
Not applicable
Showing {first} - {last} of {total} Results